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HIV/AIDS prevention and treatment
Sir—Elliot  Marseille  and  colleagues
(May  25,  p  1851),
1 used  cost-
effectiveness  analysis  to  provide  a
simplistic and outdated proposition that
prevention  of  HIV/AIDS  should  take
priority  over  and  be  funded  to  the
exclusion of treatment in Africa.
Prevention  is  almost  always  cheaper
than  care,  irrespective  of  a  country’s
development  status,  especially  if
therapeutic  options  are  dominated  by
patented  drugs.  Prevention  is  also
effective,  thus  UNAIDS  and  its
cosponsors  advocate  prevention  as  the
foundation  for  all  HIV/AIDS  pro-
grammes.  Prevention  and  treatment
have overlapping but not identical goals.
A comparison based on only one metric
can  be  instructive  but  seldom
conclusive.  No  nation’s  health  policy
strictly  enforces  trade  offs  between
prevention  and  care.  By  taking  so
narrow a view and in view of the fact
that  Africa  has  around  28  million
infected  people,  Marseille  and
colleagues  fundamentally  mis-state  the
problem.
Historically, at more than US$10 000
per  patient-year,  treatment  was  clearly
unaffordable.  As  prices  plummet  and
resources  increase,  implementation
capacity will rapidly replace finances as
the  limiting  constraint.  Prevention
efforts undoubtedly need to be scaled up
substantially. Expansion of capacity for
both  prevention  and  care  needs  time
and  incremental  increases  in  finances.
Such  efforts  are  not  simply  additive,
since every strategy improves the effect
of the other. Prevention and care involve
different  sectors  and  constituencies,
investment  in  both  simultaneously  can
achieve  more  than  would  be
accomplished by separate investment. 
Highly active antiretroviral treatment
(HAART) grants extra years of quality
life,  which  goes  beyond  price  and
generates  vast  collateral  benefits,
including  saving  the  health  system
several hundred dollars per patient-year
in averted palliative and opportunistic-
infection  care.  At  a  prevalence  of  5%,
demand for medical care is estimated to
increase  faster  than  the  public  sector’s
capacity  to  cope.  In  many  African
countries,  health  sectors  are  already
overwhelmed by AIDS in patients and
staff. HAART could save lives, money,
and  the  health  systems  themselves.  In
Namibia,  the  output  per  person  is
estimated to rise to higher than the per-
person taxes needed to fund treatment
programmes.
2
Treatment  also  has  substantial
positive  effects  on  national  develop-
ment.
3 AIDS destroys adults as workers,
parents, and care givers in the prime of
their  lives.  Treatment  saves  children
from  orphanhood;  keeps  households,
social  cohesion,  and  businesses  intact;
improves returns on social investments,
such  as  education  and  development;
increases growth and security; and keeps
to a minimum exacerbation of poverty.
As Marseille and colleagues rightly note,
HIV  has  moved  beyond  public  health
and has become a social, economic, and
security  concern,  without  appreciating
that the time scale of the larger concerns
is distinct from that in which prevention
operates.  Prevention  can  help  to  avert
such threats in the indeterminate future.
However, people, societies, economies,
and nations are at risk now because of
the  potential  of  millions  of  premature
deaths  of  those  already  infected.  Only
treatment  can  change  that  trajectory.
Countries  with  the  greatest  infection
rates  are  at  disproportionate  risk,
making  treatment  there  even  more
urgent.
The  economic  justification  for
HAART  is  its  leverage  effect  on  HIV
prevention and its potential to secure the
future  against  disabling  social  and
economic  ills.  Prioritisation  is  not  an
issue of lives today over lives tomorrow;
the  quality  of  the  future  depends
crucially on the quality of life today.
Marseille and colleagues and Andrew
Creese  and  colleagues  (May  25, 
p 1635)
4 offer static perspectives. Prices
and  resources  are  not  fixed,  especially
now.  The  commitments  made  by
African  nations  and  all  UN  Member
States  mark  unprecedented  political
momentum.
5 The epidemic has thrived
on  inabilities  to  anticipate  dynamic
effects.  Epidemiologically,  how  quickly
and  far  HIV  could  spread  was  not
foreseen; economically, policy decisions
have  frequently  been  based  on  prices
that  are  probably  obsolete  before  the
policies can be implemented. The cost
ratio of care to prevention may currently
be 28 to 1. 2 years ago it was more than
200 to 1. In 2 years time it will probably
be far lower than it is today. The price
today is less relevant than the expected
total cost, which will decline with time. 
Finally, there is no arbitrary threshold
at  which  treatment  becomes  of  value.
The decision to treat, cannot be based
only  on  narrow  variables  of  cost-
effective  analyses  but  must  involve
humanitarian considerations; and evolve
as factors, not least, prices and capacity
change. Moreover, expanding treatment
now may accelerate cost reductions by
stimulation  of  greater  supply  and
competition,  and  identification  of
cheaper  administration  mechanisms  in
resource-limited settings. 
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Sir—Andrew Creese and colleagues
1 and
Elliot  Marseille  and  colleagues
2 argue
that  treatment  of  AIDS  is  not  cost
effective in some African settings. Their
conclusions  reflect  a  depressing
backslide in the fight against the world’s
most disastrous pandemic.
The vast needs and limited resources
in  developing  countries,  where  tens  of
millions are infected, have led to endless
debate  but  little  action.  The
international  community  has  finally
responded to a pandemic that alerts the
world  to  the  threats  of  emerging  and
recrudescing  infectious  diseases  in  an
increasingly  polarised  world.  There  is
now  widespread  recognition  that  it  is 
a  strategic  and  a  moral  imperative  toFor personal use.  Only reproduce with permission from The Lancet Publishing Group.
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make  simple,  effective,  and  affordable
treatment available to as many people as
possible.
Richard  Horton
3 notes  the  need  to
provide  treatment  for  HIV/AIDS,  and
support  such  policies  as  the  Doha
Declaration,  which  affirms  countries’
rights to put their people’s health before
the  market  monopolies  of  pharma-
ceutical  companies.  Intense  opposition
to  pharmaceutical  monopolies  and
increased  market  competition  between
brand and generic drugs have led to a
fall  in  the  yearly  cost  of  triple  therapy
from  US$15 000  to  less  than  $300;
WHO  has  sourced  quality  manu-
facturers  of  affordable  antiretrovirals,
and  these  drugs  have  finally  been
included in the Essential Drugs List. 
But  now,  on  the  basis  of  flimsy
economic  data,
1 WHO  seems  to
recommend letting millions die without
effective  treatment.  WHO  is  not  an
academic institution; it is a UN agency
of substantial influence. Its mandate is
health for all, and its job is to provide
sound policy recommendations to save
and improve lives. Rather than accepting
the price of drugs as immutable, WHO
should  be  putting  more  energy  into
working  with  UNAIDS  to  bring  the
price  of  antiretrovirals  within  reach,
calling for more funding and contesting
those worldwide forces that keep billions
of people in perpetual poverty. 
Treatment  and  prevention  are
inextricably  linked;  offering  treatment
strengthens  prevention  measures,  and
prevention  is  less  effective  without
treatment. Cost-effectiveness alone is a
misguided  way  to  justify  one  over  the
other. Social and economic benefits are
vast:  children  saved  from  being
orphaned, and longer life means people
can contribute to society.
4
Cost-effectiveness  analyses  represent
a narrow viewpoint from which relevant
stakeholders are entirely excluded. Such
analyses  have  never  been  an  exclusive
prescription  for  health-care  choices  in
the developed world, and to advise the
less-developed  world  to  use  them  as
such is iniquitous. If they were applied
consistently  to  all  medical  disorders,
they  would  have  been  applied  to  the
measures that could be taken to prevent
75%  of  preventable  cardiovascular
deaths  in  the  world.
5 Narrow  cost-
effectiveness analyses of AIDS treatment
in  developing  countries  promote  a
medical  ethic  that  would  never  be
considered  in  the  developed  world,
allowing  people  to  die  when  drugs  are
available that can save them. Prevention
improves  public  health,  but  cannot
replace  treatment  of  preventable
diseases.
How are doctors in Africa to tell their
patients they cannot treat them because
it  is  not  cost  effective?  We  should  be
doing  everything  we  can  to  prevent
disease  in  the  future  while  providing
effective treatment for those who suffer
today.
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Sir—Elliot  Marseille  and  colleagues
1
make  the  case  that  antiretroviral
treatment  should  not,  in  the  near
future,  be  implemented  in  the
developing world since prevention is at
least 28 times more cost effective than
HAART. I agree with their assessment
of  the  relative  costs  of  these  two
interventions,  but  disagree  with  their
conclusions.
In  a  strict  comparison  of  cost-
effectiveness, drugs will always be more
expensive  than  condoms.  However,
data  from  cost-effectiveness  studies
have  many  limitations  and  are  highly
susceptible  to  bias  and  narrow  and
selective interpretation.
2 Marseille and
colleagues’ conclusions need to be re-
assessed, and their data need to be put
into  a  larger  socioeconomic  context
before  they  are  used  to  guide  public
policy on HIV/AIDS.
For instance, what is the cost of not
treating HIV infection in the countries
of  sub-Saharan  Africa,  where  tens  of
millions of people with HIV/AIDS now
reside? What will be the effect on: the
stability  of  businesses,  communities,
and families; countries’ gross economic
products;  degree  of  poverty;
educational  opportunities;  food,
security, and other indicators?
To  make  sweeping  recom-
mendations,  as  do  Marseille  and
colleagues, without integration of these
other kinds of effects and costs into a
decision-making  calculus  does  not
advance  evidence-based,  rational
approaches to worldwide public health.
Gregg Gonsalves
Gay Men’s Health Crisis, 119 West 24th
Street, New York, NY 10011, USA
(e-mail: greggg@gmhc.org)
Authors’ reply
Sir—Your  correspondents  all  draw
attention to important concerns in the
allocation  of  funds  between  HIV
prevention and HAART. We explicitly
addressed in our report many of these
issues,  such  as  possible  future
reductions in the costs of antiretroviral
drugs, synergies between prevention and
treatment, and the collateral benefits of
HAART.
The  technical  criticisms  are  not
relevant when considered in the context
of our methods. For example, inclusion
of saved medical care costs in estimation
of  the  benefits  of  HAART  is  often
desirable, but the estimates for the cost-
effectiveness of prevention that we cite
are also mainly unadjusted for averted
costs of medical care. Inclusion of these
averted costs would further enhance the
advantage  of  prevention.  On  balance,
our  estimate  that  prevention  saves  28
times as many years of life as HAART
per dollar spent remains defensible, and
is  probably  an  underestimate.  Rather
than a static number, we recognise that
the  exact  ratio  will  depend  on  many
biological,  behavioural,  infrastructural,
and economic factors that will vary by
setting and over time. 
All  your  correspondents  point  out
that any projection of the consequences
of  favouring  public  financing  of
prevention  versus  HAART  needs  to
account  for  the  large  social  and
economic  dynamics  in  which  the
epidemic operates. This is an important
area  of  inquiry.  Specific  findings  will
vary substantially by country. In general,
we  believe  that  after  6–8  years  in  a
country unable to finance both adequate
prevention  and  treatment,  a  strong-
treatment  approach  would  mean  not
only  more  people  being  treated  but 
also  more  symptomatic  individuals
remaining  untreated  than  would  a
strong-prevention  approach.  This  is
because with inadequate prevention, the
need for treatment further outpaces the
financial and infrastructural capacity to
deliver it. This conclusion, and indeed
most  of  our  arguments,  depends
crucially on the premise that on the time
scale  that  matters,  the  prevention/
HAART-funding  trade-off  is  real—ie,
more for one really does mean less for
the other. 
We would also like to clarify our major
conclusions. First, investing most of the
funds in prevention is the most effective